1. Home
  2. NTRA vs ZTS Comparison

NTRA vs ZTS Comparison

Compare NTRA & ZTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Natera Inc.

NTRA

Natera Inc.

HOLD

Current Price

$277.90

Market Cap

29.1B

Sector

Health Care

ML Signal

HOLD

Logo Zoetis Inc.

ZTS

Zoetis Inc.

HOLD

Current Price

$74.76

Market Cap

31.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NTRA
ZTS
Founded
2003
1952
Country
United States
United States
Employees
N/A
N/A
Industry
Medical Specialities
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
29.1B
31.9B
IPO Year
2015
2012

Fundamental Metrics

Financial Performance
Metric
NTRA
ZTS
Price
$277.90
$74.76
Analyst Decision
Strong Buy
Buy
Analyst Count
15
12
Target Price
$259.07
$154.18
AVG Volume (30 Days)
1.5M
5.3M
Earning Date
05-07-2026
05-07-2026
Dividend Yield
N/A
1.86%
EPS Growth
0.65
10.05
EPS
N/A
1.42
Revenue
$210,939,000.00
$9,467,000,000.00
Revenue This Year
$18.08
$5.63
Revenue Next Year
$19.65
$4.77
P/E Ratio
N/A
$52.62
Revenue Growth
N/A
2.28
52 Week Low
$131.81
$71.47
52 Week High
$279.42
$161.77

Technical Indicators

Market Signals
Indicator
NTRA
ZTS
Relative Strength Index (RSI) 78.21 38.76
Support Level $186.96 $74.35
Resistance Level N/A $82.66
Average True Range (ATR) 13.08 2.51
MACD 4.73 0.17
Stochastic Oscillator 99.56 30.47

Price Performance

Historical Comparison
NTRA
ZTS

About NTRA Natera Inc.

Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.

About ZTS Zoetis Inc.

Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on) and nearly 65% from companion animal (dogs, horses, cats) products. Its US business is skewed even more heavily toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.

Share on Social Networks: